神経因性疼痛（Neuropathic Pain）：グローバル治療薬予測と市場分析...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 9
1.1 List of Tables16
1.2 List of Figures 23
2 Introduction 26
2.1 Catalyst 26
2.2 Related Reports 26
3 Disease Overview 27
3.1 Clinical Manifestations of Neuropathic Pain – Signs and Symptoms 29
3.1.1 Painful Diabetic Neuropathy 31
3.1.2 Postherpetic Neuralgia 32
3.1.3 Trigeminal Neuralgia 32
3.2 Etiology and Pathophysiology 33
3.2.1 Etiology 34
3.2.2 Pathophysiology 35
4 Epidemiology 43
4.1 Diabetic Neuropathy 43
4.1.1 Disease Background 43
4.1.2 Risk Factors and Comorbidities 44
4.1.3 Global Trends 44
4.1.4 Forecast Methodology 47
4.1.5 Epidemiology Forecast for Diabetic Neuropathy (2012-2022) 57
4.1.6 Discussion 63
4.2 Postherpetic Neuralgia 65
4.2.1 Disease Background 65
4.2.2 Risk Factors and Comorbidities 66
4.2.3 Global Trends 69
4.2.4 Forecast Methodology 75
4.2.5 Epidemiological Forecast for Postherpetic Neuralgia (2012-2022) 84
4.2.6 Discussion 90
4.3 Trigeminal Neuralgia 93
4.3.1 Disease Background 93
4.3.2 Risk Factors and Comorbidities 94
4.3.3 Global Trends 95
4.3.4 Forecast Methodology 97
4.3.5 Epidemiological Forecast for Trigeminal Neuralgia (2012-2022) – Incident Cases 102
4.3.6 Epidemiological Forecast for Trigeminal Neuralgia (2012-2022) – Prevalent Cases 108
4.3.7 Discussion 113
5 Disease Management 117
5.1 Diagnosis and Treatment Overview 117
5.1.1 Diagnosis 117
5.1.2 Treatment Overview and Guidelines 124
5.2 US 134
5.2.1 Diagnosis and Referral 134
5.2.2 Drug Treatment 136
5.3 France 138
5.3.1 Diagnosis and Referral 138
5.3.2 Drug Treatment 140
5.4 Germany 142
5.4.1 Diagnosis and Referral 142
5.4.2 Drug Treatment 143
5.5 Italy 145
5.5.1 Diagnosis and Referral 145
5.5.2 Drug Treatment 147
5.6 Spain 148
5.6.1 Diagnosis and Referral 148
5.6.2 Drug Treatment 150
5.7 UK 151
5.7.1 Diagnosis and Referral 151
5.7.2 Drug Treatment 153
5.8 Japan 155
5.8.1 Diagnosis and Referral 155
5.8.2 Drug Treatment 157
6 Competitive Assessment 159
6.1 Overview 159
6.2 Tricyclic Antidepressants 164
6.2.1 Overview 164
6.2.2 Efficacy 165
6.2.3 Safety 166
6.2.4 Forecast 167
6.3 Calcium Channel Alpha-2-Delta Ligands (Anticonvulsants) 169
6.3.1 Overview 169
6.3.2 Efficacy 170
6.3.3 Safety 171
6.3.4 Forecast 172
6.3.5 Lyrica 174
6.4 Sodium Channel-Blocking Anticonvulsants (TN) 180
6.4.1 Overview 180
6.4.2 Efficacy 181
6.4.3 Safety 181
6.4.4 Forecast 182
6.5 Serotonin-Norepinephrine Reuptake Inhibitors (Antidepressants) 184
6.5.1 Overview 184
6.5.2 Efficacy 184
6.5.3 Safety 185
6.5.4 Forecast 185
6.5.5 Cymbalta 187
6.6 Opioids 191
6.6.1 Overview 191
6.6.2 Efficacy 191
6.6.3 Safety 192
6.6.4 Forecast 193
6.6.5 Nucynta ER/Palexia SR 195
6.7 Topical Therapies 200
6.7.1 Overview 200
6.7.2 Efficacy 201
6.7.3 Safety 201
6.7.4 Forecast 202
6.7.5 Lidoderm/Versatis 204
6.7.6 Qutenza 209
7 Unmet Need and Opportunity 215
7.1 Overview 215
7.2 Physician Knowledge or Awareness 216
7.2.1 Unmet Need 216
7.2.2 Gap Analysis 217
7.2.3 Opportunity 218
7.3 Diagnostic Challenges 218
7.3.1 Unmet Need 218
7.3.2 Gap Analysis 219
7.3.3 Opportunity 219
7.4 Low Treatment Rate and Underdosing of Medications 219
7.4.1 Unmet Need 219
7.4.2 Gap Analysis 221
7.4.3 Opportunity 221
7.5 Unsatisfactory Efficacy and Safety Profiles of Pharmacological Treatments 222
7.5.1 Unmet Need 222
7.5.2 Gap Analysis 223
7.5.3 Opportunity 223
7.6 Elderly Patient Population – Drug Tolerability 224
7.6.1 Unmet Need 224
7.6.2 Gap Analysis 224
7.6.3 Opportunity 225
7.7 Rational or Personalized Therapies 225
7.7.1 Unmet Need 225
7.7.2 Gap Analysis 226
7.7.3 Opportunity 226
8 Pipeline Assessment 228
8.1 Overview 228
8.2 Clinical Trial Mapping 229
8.2.1 Clinical Trials by Patient Population 229
8.3 Promising Drugs in Clinical Development 232
8.3.1 Eslicarbazepine Acetate 234
8.3.2 Topical Clonidine Gel 241
8.3.3 Cebranopadol 245
8.3.4 DS-5565 249
8.3.5 CNV-2197944 253
8.3.6 CNV-1014802 258
8.3.7 Eladur (bupivacaine patch) 262
9 Current and Future Players 267
9.1 Overview 267
9.2 Trends in Corporate Strategy 269
9.3 Company Profiles 270
9.3.1 Pfizer 270
9.3.2 Eli Lilly 272
9.3.3 Grünenthal 274
9.3.4 Endo Health Solutions 277
9.3.5 Janssen Pharmaceuticals 278
9.3.6 Daiichi Sankyo 280
9.3.7 Convergence Pharmaceuticals 282
10 Market Outlook 284
10.1 Global Markets 284
10.1.1 Forecast 284
10.1.2 Drivers and Barriers – Global Issues 294
10.2 United States 296
10.2.1 Forecast 296
10.2.2 Key Events 307
10.2.3 Drivers and Barriers 307
10.3 France 310
10.3.1 Forecast 310
10.3.2 Key Events 320
10.3.3 Drivers and Barriers 320
10.4 Germany 322
10.4.1 Forecast 322
10.4.2 Key Events 332
10.4.3 Drivers and Barriers 332
10.5 Italy 335
10.5.1 Forecast 335
10.5.2 Key Events 345
10.5.3 Drivers and Barriers 345
10.6 Spain 347
10.6.1 Forecast 347
10.6.2 Key Events 357
10.6.3 Drivers and Barriers 357
10.7 United Kingdom 359
10.7.1 Forecast 359
10.7.2 Key Events 369
10.7.3 Drivers and Barriers 369
10.8 Japan 371
10.8.1 Forecast 371
10.8.2 Key Events 381
10.8.3 Drivers and Barriers 381
11 Appendix 384
11.1 Bibliography 384
11.2 Abbreviations 403
11.3 Methodology 409
11.4 Forecasting Methodology 409
11.4.1 Diagnosed PDN, PHN, and TN Patients 409
11.4.2 Percent Drug-Treated Patients 410
11.4.3 Drugs Included In Each Therapeutic Class 410
11.4.4 Launch and Patent Expiry Dates 410
11.4.5 General Pricing Assumptions 411
11.4.6 Individual Drug Assumptions 412
11.4.7 Generic Erosion 416
11.4.8 Pricing of Pipeline Agents 416
11.5 Physicians and Specialists Included in This Study 417
11.6 About the Authors 419
11.6.1 Author 419
11.6.2 Epidemiologists 420
11.6.3 Global Head of Healthcare 421
11.7 About GlobalData 422
11.8 Disclaimer 422